-
CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its
Lifestyle Content
Technology
-
Building Onto an Existing Home Requires Construction Plans to Account for Existing Conditions
-
The Mission Motif Highlights Arts and Crafts Living During Stickley Labor Day Sale
-
Pioneering Eco Friendly Low Carbon Excellence for Metal Entrance Doors and Curtain Walls
-
Second Lines and Street Closures Can Affect Transportation Planning in New Orleans
-
Top Activewear Manufacturer Driving Sustainable Excellence in Yoga Wear
Entertainment
-
Dmitriy Pingasov Uses Aviation Experience for Athlete Transportation and Personal Travel
-
Michles & Booth Named “The Official Law Firm of UWF Athletics”
-
Wine at 38: Solaire Resort Quezon City Brings Wine Appreciation to a New Level
-
Dominate Solutions Named Tampa’s Leading Web Design Agency Behind High-Converting Plumbing and Personal Brand Websites
-
Atua AI Strengthens Enterprise AI Coordination for Decentralized Digital Operations
Health
-
American Gridwork Partners Welcomes Three Additional Companies, Expanding Physical Infrastructure Platform Across the Southeast and Ohio Valley
-
Lark Electric Joins American Gridwork Partners in Strategic Partnership to Accelerate Regional Growth and Expand Industrial Automation Capabilities
-
Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Securities Class Action
-
KKR Invests in Malaysian Healthcare Platform Avisena Healthcare
-
UNCY CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Unicycive Therapeutics, Inc. Investors
